We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Liquid Biopsy Assay for the Early Detection of Pancreatic Cancer

By LabMedica International staff writers
Posted on 29 Apr 2020
Print article
Image: This liquid biopsy blood test detects pancreatic cancer early before it metastasizes (Photo courtesy of University of Pennsylvania School of Medicine).
Image: This liquid biopsy blood test detects pancreatic cancer early before it metastasizes (Photo courtesy of University of Pennsylvania School of Medicine).
A liquid biopsy assay for multiple biomarkers enables early detection of pancreatic cancer before it metastasizes and while there are still treatment options available.

The assay, developed by investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA), was designed to detect pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC) while still in its earliest stages.

Initially, the investigators analyzed plasma samples from 204 subjects (71 healthy, 44 non-PDAC pancreatic disease, and 89 with PDAC) for the following biomarkers: carbohydrate antigen 19-9 (CA19-9), KRAS mutational burden, tumor-associated extra-cellular vesicle (EV) miRNA, and mRNA isolated on a nanomagnetic platform developed by the investigators. Circulating cell-free DNA (ccfDNA) concentration was measured by qPCR, ccfDNA KRASG12D/V/R mutations were detected by droplet digital PCR, and CA19-9 was measured by ECLIA (enhanced chemiluminescence immunoassay).

Results revealed that in a test group of 47 patients (20 with PDAC, 27 controls), the assay was 92% accurate in its ability to detect PDAC, which was better than measuring the best known PDAC biomarker, CA19-9, alone (89%). In addition, the assay was 84% accurate in determining disease staging in samples from the 25 PDAC patients who imaging showed did not have metastatic disease. This result was significantly better than that obtained by imaging alone (64% accurate).

"Right now, the majority of patients who are diagnosed already have metastatic disease, so there is a critical need for a test that can not only detect the disease earlier but also accurately tell us who might be at a point where we can direct them to a potentially curative treatment," said co-senior author Dr. Erica L. Carpenter, assistant professor of medicine at the University of Pennsylvania School of Medicine. "If validated, this test could not only provide a key tool for at-risk patients, but also a monitoring tool for patients with certain known risk factors like BRCA mutations."

The liquid biopsy assay for detection of pancreatic cancer was described in the April 16, 2020, online edition of the journal Clinical Cancer Research.

Related Links:
University of Pennsylvania School of Medicine


Print article

Channels

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.